Bioinformatics Services Provider NextGen Diagnostics Rebrands as Aperiomics

Omicia has appointed Heidi Rehm, Geoffrey Ginsberg, Thomas Quertermous, and Mark Yandell to its scientific advisory board. Rehm is director of the Laboratory for Molecular Medicine at Partners Healthcare Personalized Medicine and associate professor of pathology at Harvard Medical School. Ginsberg is director of genomic medicine at the Duke Institute for Genome Sciences & Policy, executive director of Duke's Center for Personalized Medicine and Precision, and a professor of medicine and biomedical engineering. Quertermous is the William G. Irwin professor of medicine and director of research for the division of cardiovascular medicine at Stanford University. Yandell is co-director of the University of Utah's USTAR Center for Genetic Discovery and a professor of human genetics, and a co-inventor of Omicia's VAAST and Phevor algorithms.

Adaptive Biotechnologies has tapped Dean Schorno to be chief financial officer. Schorno held leadership positions at Genomic Health over a 13-year period, including most recently as CFO, where he helped manage the launch and operations of the company's clinical lab.

Cepheid said this week that it has appointed Peter Farrell as executive vice president of international commercial operations. He replaces Philippe Jacon, who the company had named head of worldwide commercial operations in January. Jacon is transitioning to the role of president of Cepheid's High-Burden Developing Country business, replacing Paul Steuperaert, who is now focusing on the company's business in sub-Saharan Africa ahead of his 2015 retirement.

DNA Electronics this week announced the appointment of Nick McCooke as chief business officer. McCooke previously served as CEO of Solexa, which was acquired by Illumina in 2007.

See more here:
Bioinformatics Services Provider NextGen Diagnostics Rebrands as Aperiomics